Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Cystic FibrosisPseudomonas Aeruginosa
Interventions
DRUG

AZLI

AZLI 75 mg was administered 3 times daily via the investigational nebulizer.

Trial Locations (29)

13210

SUNY Upstate Medical University, Syracuse

32207

Nemours Children's Clinic - Jacksonville, Jacksonville

43205

Nationwide Children's Hospital, Columbus

46202

Riley Hospital for Children, Indianapolis

60614

Children's Memorial Hospital, Chicago

64108

Children's Mercy Hospital & Clinics, Kansas City

77030

Baylor College of Medicine, Houston

80045

The Children's Hospital - Denver, Aurora

84108

University of Utah, Salt Lake City

02115

Children's Hospital Boston, Boston

Unknown

C.H.U de Bordeaux, Bordeaux

Centre Hospitalier Robert Bissons, Lisieux

Hopital Necker Enfants Malades, Paris

Charite Campus Virchow Klinikum, Berlin

Universitatsklinik St. Josef-Hospital, Bochum

Kinder und Jugendklinik, Abteilung Lungen Bronchialheikunde, Erlandgen

Universitatsklinikum Essen, Essen

J.W. Goethe University Hopsital, Frankfurt

Azienda Ospedaliero Universitaria - Policlinico di Catania, Catania

A. Meyer Children Hospital Florence, Florence

Azienda Ospedaliera Instituti Ospitalieri di Verona, Verona

Specjalistyczny Zespot Opieki Zdrowotnej nad Matka i Dzieckiem, Gdansk

Instytut Gruzlicy I Chorob Pluc, Rabka-Zdrój

Instytut Matki i Dziecka, Warsaw

Pediatric Pneunmonology and Cystic Fibrosis Clinic, Barcelona

Hospital Infantil La Paz, Madrid

Hospital Infantil Universitario Nino Jesus, Madrid

Hospital Ramon y Cajal, Madrid

Hosp. Mat-Inf. Carlos Haya, Málaga

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY